One major catalyst for the U.S. cannabis market is cannabinoid or CBD sales. The passage of the 2018 Agriculture Improvement Act (farm bill) legalized hemp production setting the market up for a strong sales ramp.Hemp contains less than 0.3% of tetrahydrocannabinol (THC), whereas marijuana contains up to 30% of the psychoactive compound. CBD is increasingly presumed to contain properties for wellness and pain management increasing the attractiveness of hemp-infused CBD products, but the U.S. FDA has other thoughts.The FDA has questioned the lack of safety research on CBD products and placed into question the approval of edibles. In addition, CBD …read more
Source:: Yahoo Finance
